Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.
about
Cell Proliferation in NeuroblastomaRegulation of Bim in Health and DiseaseSensitization of cancer cells through reduction of total Akt and downregulation of salinomycin-induced pAkt, pGSk3β, pTSC2, and p4EBP1 by cotreatment with MK-2206.Suppression of Foxo1 activity and down-modulation of CD62L (L-selectin) in HIV-1 infected resting CD4 T cells.Inhibition of Neuroblastoma Tumor Growth by Ketogenic Diet and/or Calorie Restriction in a CD1-Nu Mouse Model.CaCO₃/CaIP₆ composite nanoparticles effectively deliver AKT1 small interfering RNA to inhibit human breast cancer growth.AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axisDanusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells.Combination of metronomic cyclophosphamide and dietary intervention inhibits neuroblastoma growth in a CD1-nu mouse model.MK-2206, an AKT inhibitor, promotes caspase-independent cell death and inhibits leiomyoma growth.Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximabPre-Clinical Evaluation of rHDL Encapsulated Retinoids for the Treatment of Neuroblastoma.Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.Proteome and Acetylome Analysis Identifies Novel Pathways and Targets Regulated by Perifosine in Neuroblastoma.Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration.The mTOR signaling pathway in pediatric neuroblastoma.New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells.AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines.PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells.Oxidative stress and lipid peroxidation products in cancer progression and therapy.Roles of PI3K/AKT/PTEN Pathway as a Target for Pharmaceutical Therapy.MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemosensitivity and apoptosis in gastric cancer by attenuation of Akt phosphorylation.A ketogenic diet supplemented with medium-chain triglycerides enhances the anti-tumor and anti-angiogenic efficacy of chemotherapy on neuroblastoma xenografts in a CD1-nu mouse model.Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer.MiR-20a-5p suppresses tumor proliferation by targeting autophagy-related gene 7 in neuroblastoma.Cell death-based treatment of neuroblastoma.p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
P2860
Q26771708-DA86E663-A5AE-4784-8AFE-51C57BA9146EQ26781203-CC6D603D-33D5-4072-B539-EAC7DD7C81AEQ33992871-EC273464-44AA-49C2-9D30-C3D0472FA1FBQ35350405-8531EB4B-09FE-430D-82ED-5DD7C994D545Q35656317-B40AA454-CA14-4FAA-B9C6-63E729771297Q35690245-B0894C3E-AB2E-480E-A213-9B6596CB6D70Q35987253-E02C6176-F0A6-4401-B9D2-F66B423CCCE3Q36324682-F288643F-3D45-4C6B-A951-691D115B3B48Q37086200-1CA80C0C-995F-496C-8013-A5F82519D730Q37240206-4BA14C58-B99F-4413-B5F9-8F2EA35BBD48Q37269197-4837353D-7565-4EC6-ABEA-ED8E297AD948Q37475635-9FD350C2-B351-40E1-863E-DDE4E100B6E5Q37613320-5A066B28-7F82-4572-8D59-134A8B8C1CE9Q37625678-F33F1A6D-320C-47B5-B2E6-DA015B02EA1BQ38103561-D4E5477A-31F6-4A21-9730-2C2E5C895C01Q38108676-7869AD2C-9434-4FE8-91AE-ED5213D3BC24Q38130615-A77C4B13-A6A4-4083-8D26-6A748017B6EEQ38962245-AB175BF5-90CF-4786-AA4E-9F615509F04BQ39208340-FE75F4B7-97E7-4BC5-8AC8-50A21F1A8DA6Q39246432-94EA1581-8826-4C58-8921-AE10BE1783C6Q41628138-3431D6D8-524E-46D9-9A03-9C13483C57A9Q41646063-501FB0E6-8865-4CC5-9FB0-26366F09FB33Q41958665-8C21972C-9952-4BF3-A5EC-3DE9A1FEDE4DQ42128983-1035F317-7D9B-4590-969B-B2F9BD033156Q42371465-12870E92-6A48-44BB-AFEF-21417CE41EE1Q47094892-821E238A-FC6D-4DC1-BB2C-72904ABAF83AQ47222421-DC868837-7D56-4693-BF8E-B92FA68ECF4EQ47839039-1C63639A-DA76-4399-BD32-C10F1DC14AD1Q48689521-A318051F-9FA6-4BE4-B5FA-74CEADAEDCECQ54315033-73F80EF8-6067-46C1-90F3-97F9C3ACD173
P2860
Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Combination of an allosteric A ...... rowth effect in neuroblastoma.
@en
Combination of an allosteric A ...... rowth effect in neuroblastoma.
@nl
type
label
Combination of an allosteric A ...... rowth effect in neuroblastoma.
@en
Combination of an allosteric A ...... rowth effect in neuroblastoma.
@nl
prefLabel
Combination of an allosteric A ...... rowth effect in neuroblastoma.
@en
Combination of an allosteric A ...... rowth effect in neuroblastoma.
@nl
P2093
P1476
Combination of an allosteric A ...... growth effect in neuroblastoma
@en
P2093
Carol J Thiele
Navid Attayan
Shuang Yan
Sridevi Ramalingam
P304
P356
10.1158/1078-0432.CCR-11-3321
P407
P577
2012-05-01T00:00:00Z